Metastatic Lung Cancer

In this video, Nathan A. Pennell, MD, PhD, highlighted a presentation from the virtual ASCO Annual Meeting, which looked at trends in molecular testing among patients with metastatic lung cancer in the U.S.

Merck voluntarily withdrew pembrolizumab’s indication in the United States for treatment of certain patients with metastatic small cell lung cancer.

The FDA granted accelerated approval to tepotinib for treatment of certain patients with metastatic non-small cell lung cancer.

In this video, Cardinale B. Smith, MD, PhD, director of quality for cancer services at Mount Sinai Health System, highlighted what oncologists have learned from managing patients throughout the COVID-19 pandemic.

In this video, Jyoti D. Patel, MD, associate vice chair for clinical research and professor of medicine at Northwestern’s Feinberg School of Medicine, discussed two presentations from the ESMO Virtual Congress 2020.

In this video, Roy S. Herbst, MD, PhD, associate cancer center director for translational research at Yale Cancer Center, highlighted Keynote 24, which was presented at ESMO Virtual Congress 2020.

Cemiplimab-rwlc monotherapy extended OS compared with first-line platinum doublet chemotherapy for certain patients with advanced non-small cell lung cancer, according to study findings presented at ESMO Virtual Congress 2020.

The FDA granted accelerated approval to pralsetinib for the treatment of adults with metastatic RET fusion-positive non-small cell lung cancer.

A number of presentations during this year’s ASCO20 Virtual Scientific Program featured data on the efficacy and safety of immunotherapy combinations for the treatment of metastatic non-small cell lung cancer.

The FDA granted accelerated approval to lurbinectedin for adults with metastatic small cell lung cancer that progressed on or after platinum-based chemotherapy.